All In Biotech

Drug Trial Radar · NCT07123402

To Evaluate the Efficacy and Safety of TRD205 Tablets in the Treatment of Chronic Postoperative Neuralgia

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Phase II Clinical Trial to Evaluate the Efficacy and Safety of TRD205 Tablets in the Treatment of Chronic Postoperative Neuralgia

Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 184 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

184

Planned (sponsor's estimate)

Start

Apr 9, 2025

Primary completion

Apr 20, 2026

Study completion May 27, 2026

Sponsor

Sponsor type
Industry
Collaborators
China-Japan Friendship Hospital
First posted
Aug 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, multicenter ,randomized, double-blind, placebo-controlled, dose-finding study designed to evaluate the efficacy and safety of TRD205 tablets in the treatment of chronic postoperative neuralgia

Conditions

  • Chronic Postoperative Neuralgia

Interventions

  • TRD205 tabletsDrug

    orally ;Take TRD205 1 tablets and Placebo 2 tablets

  • TRD205 tabletsDrug

    orally ;Take TRD205 2 tablets and Placebo 1 tablets

  • TRD205 tabletsDrug

    orally ;Take TRD205 3 tablets and Placebo 0 tablets

  • PlaceboDrug

    orally ;Take Placebo 3 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in the weekly average NRS (numeric pain rating scale,0~10:0 equated to no pain, and 10 equated to the worst pain imaginable )pain score from baseline after 6 weeks of treatmentTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.